This week from Drug Target Review...

This week from Drug Target Review...

EDITOR'S PICK

Fentanyl vaccine potential ‘game changer’ for opioid epidemic

No alt text provided for this image

A research team led by the University of Houston, US has developed a?vaccine?that targets the dangerous synthetic opioid fentanyl, which could block its ability to enter the brain and eliminate the drug’s “high”. According to the scientists, this breakthrough discovery could have major implications for the US opioid epidemic by becoming a relapse prevention agent for people trying to quit using opioids.Read more...?

===

WHAT TO READ

The next edition of Drug Target Review goes to press on 1 December. This issue will include In-Depth Focuses on: Immuno-oncology, CRISPR, Upstream Bioprocessing and Screening as well as articles covering Hit-to-Lead, Proteomics and Vaccine Development.

DOWNLOAD YOUR FREE COPY

===

TRENDING THIS WEEK

The nose-brain pathway: the intranasal administration of drugs to the CNS

Japanese scientists underwent a study exploring trigeminal nerves and how the intranasal administration of the novel glucagon-like peptide-2 can produce antidepressant effects in mice.?Read more>>>

Novel nasal vaccine strategy could improve COVID-19 protection

Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19. Read more>>>

Probiotic ‘backpacks’ show promise for treating IBD

US researchers have uncovered the uncapped potential that gut-friendly bacteria has for improving treatments of inflammatory bowel disease (IBD).?Read more>>>

Drug discovery for COPD treatments

In this article,?Drug Target Review’s?Ria Kakkad shares some of the most recent progress in discovering a drug for COPD, a disease that remains a major challenge in the medical industry. Read more>>>

===

WHAT TO WATCH

Ranging from decoding cancer inflammation to engineering cell lines and everything in between - discover our range of upcoming?live webinars and on-demand sessions?which are completely?FREE?to join.

No alt text provided for this image

FIND OUT MORE

===

JOIN THE COMMUNITY

Get your FREE subscription to Drug Target Review to?stay up to date with the?most pressing topics and trends?in?drug discovery and early-phase therapeutic development.

?Cut down on screen time by listening to our podcasts, get intimate during our webinars or sip a cup of coffee whilst flicking through our journal.?As a member, you’ll also gain exclusive access to:

  • Breaking news and features
  • Invitation to member only events
  • Unlimited archive of whitepapers, ebooks, past issues and much more…?

We provide?compelling?content contributed by the world's most respected scientists, key opinion leaders?and influencers.

SUBSCRIBE FREE TODAY

No alt text provided for this image

Want to keep up to date with our latest content? Follow us on?LinkedIn,?Facebook,?Twitter?and?YouTube.

Get involved in the conversation?#DTRTalks

要查看或添加评论,请登录

Drug Target Review的更多文章

社区洞察

其他会员也浏览了